As a part of the Viatris deal, Biocon Biologics has acquired Viatris’ rights to its biosimilar Aflibercept asset, partnered with Momenta (now Janssen), a proposed biosimilar to Regeneron’s Eylea, which is indicated for use in multiple ophthalmological indications. Viatris has been the ‘first to file’ for a biosimilar Aflibercept in the U.S.
OPHTHALMOLOGY
Ophthalmology
Aflibercept*
Filed: Filed for approval in the U.S., EU, UK and Japan
Preclinical
Clinical
Filed
Approved
Launched
*Product partnered with Momenta
